Features of treatment of patients with generalized periodontitis combined with herpesvirus infection

Abstract

Background. In Ukraine, there is a tendency to increase the frequency of periodontal disease, which reaches 90 %. The lack of data on the features of the course of Generalized Periodontitis (GP) against the background of mixed HerpesVirus Infection (HVI) and scientifically substantiated approaches to its treatment became the reason for conducting scientific research in this direction.

Aim. To increase the effectiveness of the treatment of chronic GP in patients with HVI by using differentiated immunocorrective therapy taking into account the features of the immunopathogenesis of the dental disease.

Materials & Methods. A clinical and laboratory study, examination and treatment of 100 patients with chronic Herpes Simplex Virus-1 (HSV-1) combined with genital herpes was conducted: 40 patients with HSV-1 (Group 1); 30 patients with HSV-1 and chronic Epstein-Barr Virus Infection (EBVI) (Group 2); 30 patients with EBVI (Group 3). All patients divided into subgroups 1A and 1B, 2A and 2B, 3A and 3B depending on the prescribed immunotherapy. Patients in subgroups 1A, 2A, 3A were prescribed basic therapy, antiviral therapy and immunocorrective therapy in accordance with the type of herpesvirus infection. Patients in subgroups 1B, 2B and 3B received only basic therapy and antiviral therapy. The research results were processed using the method of variational and correlation statistics using the program Statistica 10.0 for Windows (StatSoft, USA).

Research Ethics. The study was carried out in compliance with the main provisions World Medical Association Declaration of Helsinki (1964–2024), the Council of Europe Convention on Human Rights and Biomedicine (Oviedo, 2007) and the recommendations of the Committee on Bioethics under the Presidium of the National Academy of Medical Sciences of Ukraine (2002).

Results. It was found that immunocorrective therapy increases the effectiveness of treatment of patients with GP combined with GVI. No patient who received immunocorrective therapy during the year had relapses of the disease. In contrast to the comparison subgroups, GP relapses were observed in subgroup 1A in 8.3 % of patients, in subgroup 2B – in 15.3 %, in subgroup 3B – in 16.6 % of patients.

Conclusions. The inclusion of immunocorrectors in the complex therapy of patients with acute viral hepatitis enhances the effect of antiviral drugs, effectively restores the body's immunoreactivity, and alleviates the clinical course of the disease.

Keywords: dentistry, periodontal disease, immunocorrective therapy.